Indeed, several ALOX5AP inhibitors have been developed and are currently under clinical investigation as treatments for respiratory and cardiovascular diseases, such as the classical prototype MK-886 and the follow-up MK-0591, Bay-X1005, and DG-031 (first licensed by DeCode Genetics and then developed by Bayer) (68). Here, ALOX5AP is linked to cardiovascular disorder.